Comparative Pharmacology
Head-to-head clinical analysis: DISPERMOX versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISPERMOX versus VEETIDS 500.
DISPERMOX vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic